Atopic Dermatitis – Parents Of Allergic Children http://parentsofallergicchildren.org/ Thu, 24 Nov 2022 14:16:00 +0000 en-US hourly 1 https://wordpress.org/?v=5.9.3 https://parentsofallergicchildren.org/wp-content/uploads/2021/06/icon-5.png Atopic Dermatitis – Parents Of Allergic Children http://parentsofallergicchildren.org/ 32 32 Atopic Dermatitis Drugs Market Latest Trends and Future Growth https://parentsofallergicchildren.org/atopic-dermatitis-drugs-market-latest-trends-and-future-growth/ Thu, 24 Nov 2022 14:16:00 +0000 https://parentsofallergicchildren.org/atopic-dermatitis-drugs-market-latest-trends-and-future-growth/ Atopic Dermatitis Drugs Market, Atopic Dermatitis Drugs Market Size The Atopic Dermatitis Drugs Market Report 2022 is a professional and in-depth survey of the current state of the market. The report provides a basic market overview, including definitions, classifications, applications and market chain structure. Market analysis is provided for the international market, including development history, […]]]>

Atopic Dermatitis Drugs Market, Atopic Dermatitis Drugs Market Size

The Atopic Dermatitis Drugs Market Report 2022 is a professional and in-depth survey of the current state of the market. The report provides a basic market overview, including definitions, classifications, applications and market chain structure. Market analysis is provided for the international market, including development history, competitive landscape analysis, and major regions development status.

Request sample pages from this research study at –

https://www.theinsightpartners.com/sample/TIPRE00004422/?utm_source=OpenPR&utm_medium=10366

Atopic dermatitis is a chronic skin condition also known as atopic eczema. It is a type of infection (bacteria, fungi, yeasts and viruses) of the skin that results in itchy, red, swollen and cracked skin. Clear liquid can come from the affected areas and also suffer from asthma, hay fever. Eczema is more common in infants and children than in adults and very less common in their 40s. The condition can be treated with topical steroids, topical calcineurin inhibitors (TCI), and phototherapy. Certain systemic drugs (methotrexate, cyclosporine, and mycophenolate mofetil) are also used to treat flare-ups. Researchers have developed a new drug which is currently in clinical trials.

Prominent/Emerging players in the Atopic Dermatitis Drugs market study include:

MYLAN
LEO PHARMA
BAYER HEALTH
AGAIN DERMATOLOGY
NOVARTIS S.A.
BAUSCH HEALTH
ASTELLAS PHARMA INC.
AB MEDA
AGAIN DERMATOLOGY
SANOFI

Order a copy of this research study at –

https://www.theinsightpartners.com/buy/TIPRE00004422/?utm_source=OpenPR&utm_medium=10366

Market segmentation

The global atopic dermatitis drugs market is segmented on the basis of route of administration and drug class. Based on route of administration, the market is segmented into topical, injectable, and oral. On the basis of drug class, the global atopic dermatitis market is segmented into topical antibiotics, topical antihistamines, topical corticosteroids, topical moisturizers/emollients, topical calcineurin inhibitor and immunomodulators, off-label therapies, systemic agent, PDE4 and interleukin inhibitors. .

Company presentation:

The company overview provides information about the location of the company where its head office is located as well as the year established, the number of employees as of 2017, the regions where the company operates and the main areas of activity.

Product benchmark:

The product benchmarking includes the complete list of products relating to the respective market along with the application and key features.

Strategic initiatives:

Information related to new product launches, strategic collaboration, mergers and acquisitions, regulatory approvals and other company developments in the market are covered in the strategic initiatives section.

Contact us:

If you have any questions about this report or would like further information, please contact us:

North America: +1 646 491 9876

Asia-Pacific: +91 20 6727 8686

Email: sales@theinsightpartners.com

About Us:

Insight Partners are a one-stop market research provider of actionable solutions. We help our clients find solutions to their research needs through our syndicated research and advisory services. We specialize in industries such as semiconductors and electronics, aerospace and defense, automotive and transportation, healthcare, manufacturing and construction, medical devices, technology, media and telecommunications, chemicals and materials.

Our research model is very simple. We believe in customer service and provide the best quality to our customers. Through our research content, we ensure that our clients get value for money and better quality data and analysis.

Our research content is mainly focused on market trends in terms of market sizing, competitive landscape, company analysis, regional or national analysis, etc. We provide a detailed segmentation breakdown in terms of geography, technology, products and services, etc. ; which helps our clients to get deeper analysis on various research topics.

This press release was published on openPR.

]]>
ASLAN Pharmaceuticals to Participate in a Fireside Chat at the 34th Annual Piper Sandler Healthcare… | New https://parentsofallergicchildren.org/aslan-pharmaceuticals-to-participate-in-a-fireside-chat-at-the-34th-annual-piper-sandler-healthcare-new/ Mon, 21 Nov 2022 12:02:29 +0000 https://parentsofallergicchildren.org/aslan-pharmaceuticals-to-participate-in-a-fireside-chat-at-the-34th-annual-piper-sandler-healthcare-new/ SAN MATEO, Calif. and SINGAPORE, Nov. 21, 2022 (GLOBE NEWSWIRE) — ASLAN Pharmaceuticals (Nasdaq: ASLN), an immunology-focused clinical-stage biopharmaceutical company developing innovative treatments to transform the lives of patients, announced today Dr. Carl Firth, CEO, is scheduled to participate in a fireside chat during the Piper Sandler Healthcare Conference on Thursday, December 1, 2022 at […]]]>

SAN MATEO, Calif. and SINGAPORE, Nov. 21, 2022 (GLOBE NEWSWIRE) — ASLAN Pharmaceuticals (Nasdaq: ASLN), an immunology-focused clinical-stage biopharmaceutical company developing innovative treatments to transform the lives of patients, announced today Dr. Carl Firth, CEO, is scheduled to participate in a fireside chat during the Piper Sandler Healthcare Conference on Thursday, December 1, 2022 at 8:30 a.m. ET. The conference will be held from November 29 to December 1, 2022, in person at the Lotte New York Palace Hotel, New York, NY.

A replay of the fireside chat will be available on the Investor Relations section of ASLAN’s website and can be accessed directly at this link.

Management will be available for one-on-one meetings with investors throughout the conference. Please contact your Piper Sandler representative to schedule a meeting.

About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals (Nasdaq: ASLN) is an immunology-focused, clinical-stage biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is currently evaluating eblasakimaba potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and farudodstat, a potent oral DHODH enzyme inhibitor, in autoimmune diseases. ASLAN has a team in California and Singapore. For more information, visit www.aslanpharma.com or follow ASLAN on LinkedIn.

Media and IR contacts

Copyright 2022 GlobeNewswire, Inc.

]]>
A new test can help predict the condition https://parentsofallergicchildren.org/a-new-test-can-help-predict-the-condition/ Wed, 16 Nov 2022 18:13:56 +0000 https://parentsofallergicchildren.org/a-new-test-can-help-predict-the-condition/ Share on PinterestEczema is a chronic skin condition that can affect people of all ages. Brandon Bell/Getty Images Eczema is a chronic condition that affects the skin and can cause unpleasant symptoms. Predicting the development of eczema could be useful for prevention and planning effective treatment. Study results shared at the 31st Congress of the […]]]>

Share on Pinterest
Eczema is a chronic skin condition that can affect people of all ages. Brandon Bell/Getty Images
  • Eczema is a chronic condition that affects the skin and can cause unpleasant symptoms.
  • Predicting the development of eczema could be useful for prevention and planning effective treatment.
  • Study results shared at the 31st Congress of the European Academy of Dermatology and Venereology (EADV) have revealed that a non-invasive skin immune biomarker test could help doctors predict the likelihood of babies developing eczema .

Eczema is a chronic skin condition that often causes dry, itchy skin. It is prevalent in children and adults.

Experts are still researching the best way to predict the development of eczema to aid in prevention and treatment.

The results of a new study shared at the 31st Congress of the European Academy of Dermatology and Venereology (EADV) have unveiled a non-invasive test that could help predict the development of eczema in babies.

Eczema can affect people of all ages.

Genetics and factors in a person’s environment can increase the risk of developing eczema. However, it is still unclear what exactly causes eczema.

There are different types of eczema, but one of the most common types is atopic dermatitis.

Dr. Alpana Mohta, a board-certified dermatologist and medical advisor for BetterGoods.org who was not involved in the study, told Medical News Today:

“In pediatric cases, the most common form of eczema is AD [atopic dermatitis]. According to the National Eczema Association, approximately 9.6 million children under the age of 18 in the United States suffer from atopic dermatitis (AD), with one-third suffering from moderate to severe conditions. Since 1997, the prevalence of AD in children has increased dramatically, from 8% to 15% [and] 80% of people with AD develop the disease before the age of six.

Eczema often involves dry, itchy skin with rashes on areas of the body like the face and hands.

Treatment focuses on reducing symptoms and preventing further flare-ups.

A complication of eczema is skin infections. Mohta noted a few treatment options available:

Taking steps to prevent itchy skin in the first place is the key step in managing it. This can be accomplished by following a good hydration regimen and taking prescription antihistamine medications as directed. Other measures include avoiding triggers, using low pH skin cleansers, applying a cold compress, having your baby wear natural, breathable and soft fabrics that are hypoallergenic, using wrap therapy moist and a caramide-based cream or lotion.

Early identification and diagnosis can contribute to effective treatment. Some experts have focused their research efforts on ways to predict the development of eczema.

The results of the study, shared at the EADV congress in September, involved 450 children. This number included 300 full-term newborns and 150 premature newborns.

According to the results, the researchers followed the participants until they were 2 years old.

The researchers used strips of duct tape to take skin samples to test for skin biomarkers. In full-term infants, they took skin samples from the cheek and the back of the hand in the first days of life and again at 2 months. In premature infants, they took the samples between the shoulder blades during the first month of life and also from the cheek at 2 months.

The researchers reported that the specific immune biomarker, thymus and chemokine regulated by activation (TARC), was a key predictor of atopic dermatitis. If the level of this biomarker was high, babies were more likely to develop atopic dermatitis.

At the two-month marker, elevated levels of TARC were associated with the onset of atopic dermatitis before 24 months, particularly in term participants. For premature babies, elevated levels of TARC had a borderline significant association with atopic dermatitis. In term infants, elevated levels of the biomarker interleukin have been associated with the development of moderate to severe atopic dermatitis.

This identification method could be useful in the diagnosis and prevention of eczema, in particular because it is a simple and non-invasive test method.

Dr Anne-Sofie Halling, author of the study at the Department of Dermatology and Venereology at Bispebjerg Hospital in Denmark, explained the significance of the study for NTM:

“Our findings of predictive immune biomarkers collected at 2 months of age will help identify children most at risk for atopic eczema using a non-invasive and painless method, so that future preventive strategies can target only these children and preventing cases of this common disease that so many children suffer from.

Due to the sample size and methods, experts say more research is needed to confirm the study results and the effectiveness of this diagnostic method.

The results of this particular study have yet to be published in a peer-reviewed journal.

The researchers would like to point out that the lead author of the research is Professor Jacob P. Thyssen of Bispebjerg Hospital and that the study received funding from the Lundbeck Foundation.

The researchers carried out their non-invasive test method in close collaboration with Sanja Kezic of the Coronel Institute of Occupational Health in Amsterdam, an expert in the analysis of duct tape strips.

Halling was excited about the opportunities this testing method could provide in the future:

“Identifying these biomarkers is crucial to preventing atopic eczema in the future; there are currently several clinical trials on prevention strategies for atopic eczema. A recent Irish clinical trial (STOP AD trial) found that daily application of stool softeners during the first 8 weeks of life in children with a family history of eczema, asthma or rhinitis significantly reduced the incidence atopic eczema. These results confirm that there is an open window of opportunity during the first few months where a successful intervention can reduce the risk of atopic eczema, and it is also at this age that we were able to identify the immune biomarkers that predicted the development of atopic eczema.

]]>
Scar Treatment Thrives at USD 18.90 Billion with a CAGR of 10.23% by Industry Size, Share, Emerging Trends, Historical Analysis and Growth Factors https://parentsofallergicchildren.org/scar-treatment-thrives-at-usd-18-90-billion-with-a-cagr-of-10-23-by-industry-size-share-emerging-trends-historical-analysis-and-growth-factors/ Wed, 09 Nov 2022 08:36:04 +0000 https://parentsofallergicchildren.org/scar-treatment-thrives-at-usd-18-90-billion-with-a-cagr-of-10-23-by-industry-size-share-emerging-trends-historical-analysis-and-growth-factors/ The scar treatment market The report gives a well-researched summary of the major companies with substantial global holdings in terms of demand, sales, and revenue generated from the provision of premium goods and services. The scar treatment market is expected to grow between 2022 and 2032, according to the research report. During the projection period, […]]]>

The scar treatment market The report gives a well-researched summary of the major companies with substantial global holdings in terms of demand, sales, and revenue generated from the provision of premium goods and services. The scar treatment market is expected to grow between 2022 and 2032, according to the research report. During the projection period, the scar treatment industry is expected to expand at a constant CAGR.

The aim of the report is to offer a comprehensive analysis of the market, along with insightful conclusions, statistical data, historical information, market data that has been confirmed by the industry and forecasts based on sound methodology. By identifying and examining the market segments and forecasting the global market size, the study also helps in understanding the dynamics and structure of the global scar treatment market. The Scar Treatment Market report also studies the competitive positioning of key companies in terms of products, pricing, financial status, product portfolio, growth strategies, and geographic presence.

Request a Free Premium Report Sample @ https://www.quincemarketinsights.com/request-sample-64862?djtuli

Major players active in the global scar treatment market include Valeant Pharmaceuticals International, Inc., Sonoma Pharmaceuticals, Pacific World Corporation, Merz Pharma, Sientra, Inc, Velius, LLC, Smith & Nephew plc, CCA Industries, Inc, NewMedical Technology, Inc, and among others.

The research study contains essential market data such as growth influencing variables, barriers, opportunities, and strategies to overcome them. The analysis also offers industry statistics such as market value, share, CAGR, size, etc. to help new entrants in their market research. The study also covers economics, politics, technology, society, law and the environment.

The global scar treatment market is segmented on the basis of application, type, distribution channel and geography. The market is even more segmented

  • By type of scar (atrophic, hypertrophic and keloid scars and stretch marks)
  • By product (injectables, topicals and laser)
  • By end user (atrophic scars, hospitals, clinics and retail/e-commerce pharmacies)

The industry report identifies key competitors and provides strategic industry analysis of key market drivers.

Regional Analysis For Scar Treatment Market:

  • North America (United States, Canada, Mexico)
  • Europe (UK, Italy, Germany, Russia, France, Spain, Netherlands and rest of Europe)
  • Asia Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
  • South America (Colombia, Brazil, Argentina, Rest of South America)
  • Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa, Rest of Middle East and Africa)

Key factors

  • Huge technological developments with the introduction of laser therapy
  • Growing awareness of people about their aesthetic appearance
  • Development of several favorable reimbursement policies for the conduct of various scarring conditions
  • Scars or severe marks caused by road accidents
  • Reimbursement for burns, trauma and post-operative surgery

Key developments:

  • In 2017, Hologic Inc. acquired a leading aesthetic and medical technology company named Cynosure Inc. developing aesthetic treatment systems.
  • In 2017, Sonoma Pharmaceuticals received regulatory approvals for two new pediacyn for atopic dermatitis and epicyn for scar management in the UAE combined with the two microcyn (hypochlorous acid) for the treatment of keloid/hypertrophic scars and atopic dermatitis in Singapore.
  • In 2017, CCA Industries, Inc. entered into an independent licensing agreement with Ultimark Products, LLC for the commercialization rights to the “Porcelana” brand, the worldwide skin tightening product.

Contents

Global Scar Treatment Market Research Report

  1. Scar Treatment Market – Overview
  2. Scar Treatment Market – Executive Summary
  3. Scar Treatment Market – Benchmarking
  4. Scar Treatment Market Forces
  5. Scar Treatment Market – Strategic Analysis
  6. Scar Treatment Market – By Product Type (Market Size – USD Million/USD Billion)
  7. Scar Treatment Market – By Application (Market Size – USD Million/Billion)
  8. Scar Treatment Market – By Distribution Channel (Market Size – USD Million/USD Billion)
  9. Scar Treatment Market – By Geography (Market Size – USD Million/USD Billion)
  10. Scar Treatment Market – Entropy
  11. Business Analysis of the Scar Treatment Market

This report aims to provide:

  • A qualitative and quantitative review of current trends, dynamics and projections from 2022 to 2032.
  • SWOT analysis and Porter’s five forces analysis are used to describe the ability of buyers and suppliers to make profit-oriented decisions and improve their business.
  • An in-depth study of market segmentation helps identify current market opportunities.
  • Finally, by presenting balanced information under one roof, this scar treatment report saves you time and money.

The research study can answer the following key questions:

  1. What will be the progress rate of the scar treatment market for the conjecture period 2032?
  2. What are the major factors driving the scar treatment market across different regions?
  3. Who are the major vendors dominating the scar treatment industry and what are their winning strategies?
  4. What will be the scope of the contract for the estimated period?
  5. What are the big trends shaping the expansion of the industry in the coming years?
  6. What are the challenges faced by the Scar Treatment Market?

Do you have questions or requests? Ask our industry expert: https://www.quincemarketinsights.com/enquiry-before-buying/enquiry-before-buying-64862?djtuli

About Us:

QMI has the most comprehensive collection of market research products and services available on the web. We provide reports from virtually all major publications and regularly update our list to provide you with immediate online access to the world’s most comprehensive and up-to-date archive of professional market, company, property and model information. global.

Contact us:

Overview of the quince market

Office no. 306, 307

Park Plaza Business Center

Pune, Maharashtra 411028

Phone: APAC +91 706 672 4848 / USA +1 208 405 2835 / UK +44 1444 39 0986

E-mail: [email protected]

]]>
As winter sets in, the one thing our skin needs most is a good moisturizer: The Tribune India https://parentsofallergicchildren.org/as-winter-sets-in-the-one-thing-our-skin-needs-most-is-a-good-moisturizer-the-tribune-india/ Sun, 06 Nov 2022 03:49:00 +0000 https://parentsofallergicchildren.org/as-winter-sets-in-the-one-thing-our-skin-needs-most-is-a-good-moisturizer-the-tribune-india/ Dr Vikas Sharma Currently, the incidence of dry skin conditions is on the rise due to urbanization, tampering, pollution, and the abandonment of traditional massage and oil baths. Dryness is not a single entity but is characterized by differences in skin chemistry and morphology depending on internal and external stressors. Dry skin is noted when […]]]>

Dr Vikas Sharma

Currently, the incidence of dry skin conditions is on the rise due to urbanization, tampering, pollution, and the abandonment of traditional massage and oil baths. Dryness is not a single entity but is characterized by differences in skin chemistry and morphology depending on internal and external stressors.

Dry skin is noted when the moisture content is less than 10% and there is a loss of continuity of the top layer of skin.

Moisturizers prevent and treat dry skin, but that’s not all. Moisturizers protect sensitive skin, improve skin tone and texture, and hide blemishes. During this season, the one thing our skin needs the most is a good moisturizer.

save your skin

Many moisturizers are available in the market. Just like finding a good cleanser, finding the perfect moisturizer for skin can be tricky. Even if a particular moisturizer doesn’t give you acne, some moisturizers are too oily and heavy or just aren’t “moisturizing” enough.

Which moisturizer is best for you depends on many factors, including skin type, age, and whether you have specific skin conditions, such as acne, atopic dermatitis, psoriasis, eczema, etc. or systemic disorders such as diabetes, thyroid disorders, sarcoidosis, etc.

normal skin: Normal skin is neither too dry nor too oily. To maintain this natural moisture balance, use a water-based moisturizer that has a light, non-greasy feel. These moisturizers often contain light oils, such as cetyl alcohol, or silicone-derived ingredients, such as cyclomethicone.

Dry skin: To restore moisture to dry skin, you need a heavier oil-based moisturizer that contains ingredients such as antioxidants, grapeseed oil or dimethicone, which helps keep the skin hydrated for 24 hours. For very dry, cracked skin, petrolatum-based products are best. They have longer hold than creams and are more effective in preventing water from evaporating from our skin.

oily skin: Oily skin is prone to acne and breakouts. Although oily, such skin still needs hydration, especially after using skincare products that remove oils and dry out the skin. A light moisturizer can also help protect the skin after washing. Choose a water-based product labeled “non-comedogenic,” which means it won’t clog pores.

Sensitive skin: Sensitive skin is susceptible to skin irritation, redness, itching or rashes. Look for a moisturizer that contains soothing ingredients such as chamomile or aloe and is free of potential allergens, such as fragrances or dyes. Also avoid products containing acids such as lactic or glycolic acids, which can irritate sensitive skin.

mature skin: As we age, the skin tends to become drier as the sebaceous glands become less active. To keep skin soft and well hydrated, choose an oil-based moisturizer that contains petroleum jelly as a base, as well as antioxidants or alpha hydroxy acids to fight wrinkles. These ingredients help absorb moisture and prevent flaky, scaly skin. These moisturizers keep the skin hydrated and supple. They lock in the skin’s natural moisture and help draw moisture to the surface of the skin to prevent it from drying out. They also improve skin barrier function.

(Dr Sharma is a Dermatologist based in Chandigarh)

]]>
Targeted biomedicines to debut at CIIE and bring relief to patients https://parentsofallergicchildren.org/targeted-biomedicines-to-debut-at-ciie-and-bring-relief-to-patients/ Fri, 04 Nov 2022 01:00:00 +0000 https://parentsofallergicchildren.org/targeted-biomedicines-to-debut-at-ciie-and-bring-relief-to-patients/ Sanofi participates in the CIIE for the 5th consecutive year. The China International Import Expo is in its fifth year. Over the past five years, the CIIE has become an important platform for the world to share China’s development opportunities. As a global leader in pharmaceutical and healthcare innovation, Sanofi has participated in the CIIE […]]]>

Sanofi participates in the CIIE for the 5th consecutive year.

The China International Import Expo is in its fifth year. Over the past five years, the CIIE has become an important platform for the world to share China’s development opportunities. As a global leader in pharmaceutical and healthcare innovation, Sanofi has participated in the CIIE for five consecutive years. Again this year, the company will be showcasing a new drug for children 6 months to 5 years old called Dupixent® (Dupilumab). The product treats inflammation-induced atopic dermatitis (AD) type 2, aiming to meet the health needs of younger patients with AD and to accelerate an innovative treatment plan to benefit patients of all ages who are affected by AD.

In recent years, Sanofi has continued to advance scientific development as well as standards and models for AD diagnosis and treatment and promoted the improvement of standardized diagnosis and treatment systems and long-term management of AD. in China. It is reported that the special issue of “100 questions and answers for Chinese patients with Alzheimer’s disease” jointly published by more than 20 authoritative experts in the field of dermatology, supported by Sanofi, sponsored by the professional committee Dermatology Rehabilitation Program of the Chinese Rehabilitation Medical Association, and led by Professor Zhang Jianzhong, Director of the Department of Dermatology of Peking University People’s Hospital, will also be unveiled at this year’s CIIE.

Cablivi®, the world’s first approved nanobody drug and targeted drug for the treatment of Acquired Thrombocytopenic Thrombotic Purpura (TTTP), was nominated for this year’s “Best Biotechnology Product Award” at the Galen Awards and will also be featured at the CIIE. A next-generation enzyme replacement therapy (ERT) drug for the treatment of Pompe disease, Nexviazyme®, will also be introduced to the public for the first time at the 5th CIIE. Nexviazyme® has already received “Breakthrough Therapy” designation from the FDA. The drug can significantly improve respiratory function and exercise capacity in patients with Pompe disease and aims to become the standard treatment for Pompe disease.

]]>
What Your Couple’s Halloween Costume Says About The Relationship https://parentsofallergicchildren.org/what-your-couples-halloween-costume-says-about-the-relationship/ Tue, 01 Nov 2022 10:04:01 +0000 https://parentsofallergicchildren.org/what-your-couples-halloween-costume-says-about-the-relationship/ Image source: Getty/wundervisuals Halloween is one of the best days of the year for couples. Not only can you kick off your relationship on Instagram with a sexy couples costume, but you can also learn a little more about your partner based on their Halloween costume preferences. Do they prefer a cheap do-it-yourself Halloween costume […]]]>

Image source: Getty/wundervisuals

Halloween is one of the best days of the year for couples. Not only can you kick off your relationship on Instagram with a sexy couples costume, but you can also learn a little more about your partner based on their Halloween costume preferences.

Do they prefer a cheap do-it-yourself Halloween costume for couples or do they opt for a fun Halloween costume? Do they spend months before the October 31 holiday thinking about their costume, or do they come up with a last-minute couples costume idea the night before? Whatever their answers are, it’s all incredible information about what your future with this person could look like, even beyond Halloween.

But knowing more about your partner doesn’t stop there. Turns out, there might be some real psychology behind what your couple’s Halloween costume says about your relationship.

“Choosing a Halloween costume that’s in tune with your partner can definitely be an indicator of relationship strength,” licensed psychologist Lindsay Popilskis, PhD, tells POPSUGAR.

Although she clarifies that there are “significantly better and more reliable indicators that can be used to determine the status of a relationship”, the couples costume that you and your partner both decide on could mean more. deep. For fun, let’s take a look at the most popular couples’ Halloween costumes and what they might say about your relationship. (And please, I strongly encourage you to send this to your partner to check us out.)

A classic pop culture reference

Think: Sandy and Danny from “Grease” or Baby and Johnny from “Dirty Dancing”

You and your partner probably like to keep things a little traditional, says Andrea Dindinger, licensed therapist and relationship coach. It could mean that your relationship is very similar to the “old school” way of dating, and you’re not necessarily looking to change things up anytime soon. Not to be confused with being regressive, however, chances are you just enjoy chivalry here and there. It may warm your heart when your partner walks on the side of the street closest to the cars. Maybe you would like your partner to ask your parents for permission to propose. Either way, you and your lover “probably expect their partner to behave stereotypically and reliably,” Dindinger adds.

A classic Halloween costume

Think: a nurse and a patient or a devil and an angel

These typical costumes have proven themselves, and “the same can be said of your relationship,” says Dr. Popilskis. This means that your relationship “has a high level of comfort based on trust and intimacy”. Although your relationship might be somewhat misinterpreted as “basic,” it’s likely that you and your partner like to play it safe, which doesn’t have to be a bad thing.

A recent pop culture moment in 2022

Think: Rue and Jules from “Euphoria” or Anthony and Kate from “Bridgerton”

If there was one adjective to describe your relationship, it would be “spontaneous”. Dr. Popilskis says that you and your person “probably live in the moment” and don’t think too far into the future. “You’re not the type of couple to dwell on past mistakes or worry about what the future holds for both of you,” she says. “Instead, you go with the flow and are able to enjoy being in each other’s presence in the moment.” Basically, you’re all the adrenaline junkies in your group of friends who refuse to plan more than 10 days.

A superhero reference

Think: Spider-man and Mary Jane or Batman and Batwoman

Did someone say “power torque”? In this relationship, you and your partner are likely to “work hard, play hard, and expect the best out of [each other]You’re probably each other’s greatest cheerleaders, pushing each other to become even better versions of yourselves — mentally, physically, and by winning the pickleball tournament. of the weekend.

A funny (or punny) couple costume

Think: ketchup and mustard or salt and pepper

OK, we get it, you two are probably the funniest people in the room. After all, “this couple loves to have fun and be playful,” Dindinger says. But even beyond that, you’re both “independently dependent,” says Dr. Popilskis. “You both know how to have a good time alone and you don’t mind being the center of attention individually, but you’re happiest and strongest when you’re together.” In other words, you do not complete your partner, but you complete him. Think of yourself as the pea in your partner’s pod – maybe even literally.

]]>
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Brief Update on Interests https://parentsofallergicchildren.org/arcutis-biotherapeutics-inc-nasdaqarqt-brief-update-on-interests/ Sat, 29 Oct 2022 13:33:36 +0000 https://parentsofallergicchildren.org/arcutis-biotherapeutics-inc-nasdaqarqt-brief-update-on-interests/ Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Rating) was the target of a significant increase in short-term interest in October. As of October 15, there was short interest totaling 6,850,000 shares, an increase of 14.4% from the total of 5,990,000 shares as of September 30. Currently, 16.4% of the stock’s shares are sold short. Based on […]]]>

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Rating) was the target of a significant increase in short-term interest in October. As of October 15, there was short interest totaling 6,850,000 shares, an increase of 14.4% from the total of 5,990,000 shares as of September 30. Currently, 16.4% of the stock’s shares are sold short. Based on an average trading volume of 753,600 shares, the short-term interest rate ratio is currently 9.1 days.

Arcutis Biotherapeutics Stock Performance

Arcutis Biotherapeutics stock opened Friday at $17.50. Arcutis Biotherapeutics has a 1-year low of $13.59 and a 1-year high of $27.40. The company has a 50-day simple moving average of $20.21 and a 200-day simple moving average of $21.19. The company has a debt ratio of 0.37, a current ratio of 10.75 and a quick ratio of 10.75.

Arcutis Biotherapeutics (NASDAQ:ARQT – Get Rating) last reported results on Thursday August 4th. The company reported ($1.31) earnings per share (EPS) for the quarter, beating analyst consensus estimates of ($1.38) by $0.07. Sell-side analysts expect Arcutis Biotherapeutics to post -5.6 earnings per share for the current year.

Wall Street analysts predict growth

Several analysts have recently released reports on the stock. Goldman Sachs Group raised its price target on Arcutis Biotherapeutics shares from $45.00 to $50.00 and gave the company a “buy” rating in a Tuesday, Aug. 2 research note. Jonestrading reaffirmed a “buy” rating and set a price target of $54.00 on Arcutis Biotherapeutics shares in a Thursday, September 22 research note. Needham & Company LLC assumed coverage for Arcutis Biotherapeutics stock in a Wednesday, September 7 research note. They set a “buy” rating and a price target of $46.00 for the company. Finally, Morgan Stanley raised its price target on Arcutis Biotherapeutics shares from $46.00 to $49.00 and gave the company an “overweight” rating in a Tuesday, Oct. 4 research note. Six equity research analysts rated the stock with a buy rating. According to MarketBeat.com, Arcutis Biotherapeutics has a consensus rating of “Buy” and a consensus price target of $51.20.

Insiders place their bets

In other Arcutis Biotherapeutics news, Director Howard G. Welgus sold 6,000 shares of the company in a trade dated Tuesday, October 4. The shares were sold at an average price of $20.29, for a total value of $121,740.00. Following completion of the transaction, the administrator now owns 168,208 shares of the company, valued at $3,412,940.32. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. During the last quarter, insiders sold 14,000 shares of the company worth $311,560. Insiders of the company hold 23.00% of the shares of the company.

Institutional investors weigh in on Arcutis Biotherapeutics

A number of institutional investors have recently bought and sold shares of ARQT. Frazier Life Sciences Management LP acquired a new stake in Arcutis Biotherapeutics during the first quarter valued at approximately $162,443,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Arcutis Biotherapeutics during the first quarter for a value of approximately $29,000. Nisa Investment Advisors LLC acquired a new stake in Arcutis Biotherapeutics during the first quarter valued at approximately $268,000. Allspring Global Investments Holdings LLC increased its stake in Arcutis Biotherapeutics by 3.3% during the second quarter. Allspring Global Investments Holdings LLC now owns 629,754 shares of the company worth $13,420,000 after purchasing an additional 20,106 shares during the period. Finally, Tekla Capital Management LLC increased its stake in Arcutis Biotherapeutics by 13.1% during the second quarter. Tekla Capital Management LLC now owns 148,874 shares of the company worth $3,173,000 after purchasing an additional 17,241 shares during the period.

Arcutis Biotherapeutics Company Profile

(Get an evaluation)

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, is focused on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.

Read more

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to contact@marketbeat.com.

Before you consider Arcutis Biotherapeutics, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Arcutis Biotherapeutics didn’t make the list.

While Arcutis Biotherapeutics currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the five actions here

]]>
MAC Cosmetics x Black Panther: Wakanda Forever Collection https://parentsofallergicchildren.org/mac-cosmetics-x-black-panther-wakanda-forever-collection/ Wed, 26 Oct 2022 22:32:02 +0000 https://parentsofallergicchildren.org/mac-cosmetics-x-black-panther-wakanda-forever-collection/ As POPSUGAR editors, we independently curate and write things we love and think you’ll love too. If you purchase a product that we have recommended, we may receive an affiliate commission, which in turn supports our work. MAC Cosmetics has teamed up with Marvel for a limited-edition Wakandan-inspired makeup collection in honor of “Black Panther: […]]]>

As POPSUGAR editors, we independently curate and write things we love and think you’ll love too. If you purchase a product that we have recommended, we may receive an affiliate commission, which in turn supports our work.

MAC Cosmetics has teamed up with Marvel for a limited-edition Wakandan-inspired makeup collection in honor of “Black Panther: Wakanda Forever,” which hits theaters November 11. The line mirrors how the characters look in the film with shades flattering all skin tones. tones. Whether you love Ramonda’s regal makeup or prefer something bold and empowering like Dora Milaje could wear, there are lipsticks, eye shadows and more to help you channel your inner superhero. .

The MAC Cosmetics x “Black Panther: Wakanda Forever” collection includes four lipsticks, four liquid lipsticks, one gold lip gloss, one eight-shadow palette, one black pencil eyeliner, two liquid liners, two highlighters and two makeup brushes. The packaging features Black Panther’s black and silver superhero costume, along with purple accents representing the powers given by the heart-shaped grass. There is a balance between everyday wearable shades and bold, vibrant hues, making it ideal for a wide range of looks. Plus, the gold shimmer and highlighter are perfect for adding that glam factor for the holiday season and beyond.

MAC Cosmetics x Marvel’s “Black Panther: Wakanda Forever” limited edition will officially launch on the MAC Cosmetics website on November 1, but you can preview the entire lineup coming soon.

]]>
Atopic Dermatitis – Drug Pipeline Landscape, 2022 https://parentsofallergicchildren.org/atopic-dermatitis-drug-pipeline-landscape-2022/ Mon, 24 Oct 2022 05:04:00 +0000 https://parentsofallergicchildren.org/atopic-dermatitis-drug-pipeline-landscape-2022/ Global Analysis Services Global Insight Services recently released Atopic Dermatitis – Drug Pipeline Landscape 2022 report. The pipeline landscape report provides analysis of pipeline products based on multiple development stages ranging from discovery to pre-registration . Request a sample report: https://www.globalinsightservices.com/request-sample/GIS31002 Atopic dermatitis (eczema) is a condition that causes dry, itchy, and inflamed skin. It […]]]>

Global Analysis Services

Global Insight Services recently released Atopic Dermatitis – Drug Pipeline Landscape 2022 report. The pipeline landscape report provides analysis of pipeline products based on multiple development stages ranging from discovery to pre-registration .

Request a sample report: https://www.globalinsightservices.com/request-sample/GIS31002

Atopic dermatitis (eczema) is a condition that causes dry, itchy, and inflamed skin. It is characterized by inflamed skin that may split open and release clear fluid when scratched. Eczema damages the skin barrier function which makes the skin more sensitive and more prone to infection and dryness.

Atopic dermatitis is caused by a combination of immune system activation, genetics, environmental triggers, and stress. Weak skin barrier function can also trigger an immune system response that causes inflamed skin and other symptoms.

Symptoms of atopic dermatitis (eczema) include dry, cracked skin, itching, rashes, bumps, on brown or black skin, oozing and crusting, thickened skin, darkening of the skin around the eyes, sensitive skin from scratching.

Report Highlights

Global Insight Service’s 2022 report, Atopic Dermatitis – Drug Pipeline Landscape, provides an overview of drugs in the pipeline for atopic dermatitis. This report covers detailed information on atopic dermatitis drugs in development, evaluation by target, mechanism of action, route of administration and molecule type. Product portfolio by company, development stage and key regulatory designations, agreements and milestones have been presented to provide information and thus help industry players in their decision-making. The Atopic Dermatitis Pipeline report helps in understanding the drugs that are in the development stage of the drug development process globally.

Scope

The pipeline landscape report provides an analysis of pipeline products based on multiple development stages ranging from discovery to pre-registration. The report provides a review of the companies’ in-process therapeutics based on information from company and industry specific sources. The pipeline report covers the evaluation of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA), and molecule type. Full pipeline product profiles with details such as company overview, stage of development; Molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key agreements, clinical trials, and major upcoming milestones are included.

Find out before you buy: https://www.globalinsightservices.com/inquiry-before-buying/GIS31002

Report segmentation
– Assessment by stage of development
– Evaluation by companies
– Evaluation by target
– Assessment by mechanism of action
– Evaluation by type of molecule
– Evaluation by route of administration

Some of the key players involved in the development of atopic dermatitis therapeutics are:

• 3SBio Inc.
• AbbVie
• Aclaris Therapeutics, Inc.
• Akaal Pharma Pty Ltd
• Akesobio Australia Pty Ltd
• Allakos, Inc.
• Amgen
• Amtixbio Co Ltd
• Amytrx Therapeutics, Inc.
• AOBiome LLC
• Arcutis Biotherapeutics, Inc.
• Arena Pharmaceuticals
• Arjil Pharmaceuticals LLC
• Asana BioSciences
• ASLAN Pharmaceuticals
• Astra Zeneca
• Atrapos Therapeutics LLC
• Avixgen Inc.
• Azitra Inc.
• BenevolentAI Bio
• BioMarck Pharmaceuticals Ltd.

Methodology

The research process includes extensive secondary research of public domain and other authentic sources to add or update pipeline product information. Secondary research sources include, but are not limited to, company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences and clinical trial registries.

Contact us:

Global Insight Services LLC
16192 Coast Road, Lewes DE 19958
Email: info@globalinsightservices.com
Phone: +1-833-761-1700
Website: https://www.globalinsightservices.com/

About Global Insight Services:

Global Insight Services (GIS) is a leading multi-industry market research company headquartered in Delaware, USA. We are committed to providing our clients with the highest quality data, analysis and tools to meet all of their market research needs. With GIS, you can be assured of quality deliverables, a robust and transparent research methodology, and superior service.

This press release was published on openPR.

]]>